下一代生物治疗药物:对后生物药物作为治疗儿科亚托皮性皮肤炎的系统审查和网络元分析
Carol Stephanie C Tan Lim1, Ma Easter Joy V Sajo2, Khianne Ed Miguel P Orteza2
1Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
概括
乳杆菌 rhamnosus IDCC 3201 (LR) 显示了对儿科亚托邦性皮肤炎 (AD) 的潜在益处. 建议进行进一步的研究,以确认其在治疗AD症状中的有效性和安全性.
科学领域:
- 微生物学 微生物学
- 皮肤病学 皮肤病学
- 生物治疗学 生物治疗学
背景情况:
- 针对阿托皮性皮炎 (AD) 的后生物药领域还处于新生阶段,缺乏直接的比较研究和网络元分析.
- 现有研究尚未对儿童AD的各种后生物菌株的生物治疗潜力进行合成.
结论:
- 拉科巴西勒斯 (Lactobacillus rhamnosus) IDCC 3201 (LR) 对患有亚托邦性皮肤炎的儿童显示出有前途的治疗益处.
- 这些发现表明,LR需要进一步研究其在治疗儿科阿尔茨海默病中的作用.
- 虽然Lactobacillus paracasei GM080 (LP2) 在安全性方面排名最高,但它在减少AD症状方面的有效性并不显著.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
348
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
348
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200


